The M-CSF receptor in osteoclasts and beyond
SH Mun, PSU Park, KH Park-Min - Experimental & molecular medicine, 2020 - nature.com
Colony-stimulating factor 1 receptor (CSF1R, also known as c-FMS) is a receptor tyrosine
kinase. Macrophage colony-stimulating factor (M-CSF) and IL-34 are ligands of CSF1R …
kinase. Macrophage colony-stimulating factor (M-CSF) and IL-34 are ligands of CSF1R …
Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
DA Hume, KPA MacDonald - … Journal of the American Society of …, 2012 - ashpublications.org
Macrophage-colony stimulating factor (CSF-1) signaling through its receptor (CSF-1R)
promotes the differentiation of myeloid progenitors into heterogeneous populations of …
promotes the differentiation of myeloid progenitors into heterogeneous populations of …
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
KG Roberts, Y Li, D Payne-Turner… - New England journal …, 2014 - Mass Medical Soc
Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL …
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL …
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha… - Cancer cell, 2014 - cell.com
Macrophage infiltration has been identified as an independent poor prognostic factor in
several cancer types. The major survival factor for these macrophages is macrophage …
several cancer types. The major survival factor for these macrophages is macrophage …
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 …
PA Cassier, A Italiano, CA Gomez-Roca… - The Lancet …, 2015 - thelancet.com
Background Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue
(alternatively known as pigmented villonodular synovitis), an orphan disease with unmet …
(alternatively known as pigmented villonodular synovitis), an orphan disease with unmet …
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer
J Xu, J Escamilla, S Mok, J David, S Priceman, B West… - Cancer research, 2013 - AACR
Radiotherapy is used to treat many types of cancer, but many treated patients relapse with
local tumor recurrence. Tumor-infiltrating myeloid cells (TIM), including CD11b (ITGAM)+ …
local tumor recurrence. Tumor-infiltrating myeloid cells (TIM), including CD11b (ITGAM)+ …
RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF‐κB pathway in oral squamous cell carcinoma
H Dan, S Liu, J Liu, D Liu, F Yin, Z Wei… - Molecular …, 2020 - Wiley Online Library
Receptor for activated C kinase 1 (RACK1) has been shown to promote oral squamous cell
carcinoma (OSCC) progression, and RACK1 expression levels have been negatively …
carcinoma (OSCC) progression, and RACK1 expression levels have been negatively …
Is target-based drug discovery efficient? Discovery and “off-target” mechanisms of all drugs
A Sadri - Journal of medicinal chemistry, 2023 - ACS Publications
Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …
Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal …
CD Blanke, GD Demetri, M Von Mehren… - Journal of clinical …, 2008 - ascopubs.org
Purpose The outcome of patients diagnosed with advanced gastrointestinal stromal tumor
(GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a …
(GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a …
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors …
CD Blanke, C Rankin, GD Demetri, CW Ryan… - Journal of clinical …, 2008 - ascopubs.org
Purpose To assess potential differences in progression-free or overall survival when
imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors …
imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors …